ACADIA Pharma (ACAD) Stock Forecast & Price Target

ACADIA Pharmaceuticals Inc. is experiencing robust commercial growth, particularly with NUPLAZID and DAYBUE, which has led to an optimistic FY26 revenue guidance of $460 million to $490 million, indicating potential upside to prior consensus estimates. The company reported stronger-than-expected sales for DAYBUE in 4Q, achieving $110 million with a 13% year-over-year growth, attributed to increased US community uptake and international demand, alongside a strong net patient addition globally. Furthermore, ACADIA's strategic expansion of their field force and recent intellectual property wins bolster confidence in sustaining revenues, projecting combined net sales of approximately $1.7 billion by 2028, affirming the strength of their core business.

The analysis of ACADIA Pharmaceuticals, Inc. reveals several fundamental challenges contributing to a negative outlook on its stock. Key risks include potential failures in gaining approvals for new indications, uncertainty around market uptake of existing products NUPLAZID and DAYBUE, and the emergence of negative safety signals that may inhibit market access or result in product removals. Additionally, the recent unfavorable CHMP trend vote for trofinetide, coupled with high dropout rates in clinical studies and mixed expert feedback on efficacy, raises concerns about future revenue generation in the European market amidst pressures from reimbursement and regulatory environments.